FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1760504346> ?p ?o ?g. }

• W1760504346 endingPage "184" @default.
• W1760504346 startingPage "184" @default.
• W1760504346 abstract "Vinorelbine (Navelbine) is a new vinca alkaloid with superior efficacy compared to older drugs such as vincristine, vinblastine, and vindesine. Unlike the older vinca alkaloids, neuromuscular toxicity is not a major problem. However, myelosuppression (especially granulocytopenia) is the major dose-limiting toxicity. Nonmyelosuppressive toxicity is minimal, although venous irritation can be a major problem. This can be mitigated with shorter infusion times of 5 to 10 minutes. Vinorelbine is the first drug in over 20 years to be FDA-approved for NSCLC. The older approved drugs, nitrogen mustard, methotrexate and doxorubicin, are not felt to have clinical value. The approval was based upon two phase III studies. An industry-sponsored American study compared Navelbine 30 mg/m2 weekly versus 5-FU plus leucovorin in 216 patients. MST was 30 versus 22 weeks, with one-year survivals of 25% versus 16% (p = 0.03). Response rates were 12% versus 3%. The second study was a three-arm European study comparing vinorelbine (30 mg/m2) versus cisplatin (120 mg/m2) and either vinorelbine or vindesine. Six hundred twelve patients were entered. Response rates were 14%, 30%, and 19%, with MST. 31, 40, and 32 weeks (p = 0.04 favoring cisplatin + vinorelbine). Post-FDA approval, SWOG reported a phase III study comparing cisplatin (100 mg/m2) every four weeks with or without vinorelbine (25 mg/m2/week). Response rates (in 432 patients) were 10% versus 26% and MST six versus eight months with one-year survivals of 16.4% versus 35.4%. Two other vinorelbine phase III studies are noteworthy. A Japanese study evaluated weekly vinorelbine (25 mg/m2) versus vindesine (3 mg/m2). Response rates were 29% versus 9% in 150 patients, with MST 12 versus 10 months. Finally, a phase III study of 231 patients compared vinorelbine (30 mg/m2/week) ± cisplatin (80 mg/m2 q 3 weeks). Response rates were 16% versus 43%, but no difference in survival (32 versus 33 weeks: p = 0.48). Current cooperative group studies will compare cisplatin + vinorelbine to carboplatin + paclitaxel (SWOG), evaluate cisplatin + vinorelbine with XRT in stage III disease (CALGB), and evaluate cisplatin + vinorelbine as postoperative adjuvant therapy for stage I (T2NO) and stage II NSCLC (NCI-Canada and ECOG). Vinorelbine also has activity in ovarian and breast cancer, and possibly prostate cancer. A study from Argentina evaluated vinorelbine 30 mg/m2/week as first-line chemotherapy in metastatic breast cancer. There was a 41% response rate in 44 patients. An industry-supported multi-institutional American study had similar results. Vinorelbine has also been evaluated in metastatic breast cancer patients with prior chemotherapy. Most studies demonstrated activity with mild toxicity." @default.
• W1760504346 created "2016-06-24" @default.
• W1760504346 creator A5048660181 @default.
• W1760504346 date "1997-06-01" @default.
• W1760504346 modified "2023-09-26" @default.
• W1760504346 title "Navelbine: How I Use It" @default.
• W1760504346 doi "https://doi.org/10.1634/theoncologist.2-3-184" @default.
• W1760504346 hasPublicationYear "1997" @default.
• W1760504346 type Work @default.
• W1760504346 sameAs 1760504346 @default.
• W1760504346 citedByCount "0" @default.
• W1760504346 crossrefType "journal-article" @default.
• W1760504346 hasAuthorship W1760504346A5048660181 @default.
• W1760504346 hasBestOaLocation W17605043461 @default.
• W1760504346 hasConcept C126322002 @default.
• W1760504346 hasConcept C141071460 @default.
• W1760504346 hasConcept C143998085 @default.
• W1760504346 hasConcept C2776553716 @default.
• W1760504346 hasConcept C2776694085 @default.
• W1760504346 hasConcept C2776755627 @default.
• W1760504346 hasConcept C2777096885 @default.
• W1760504346 hasConcept C2777132456 @default.
• W1760504346 hasConcept C2778239845 @default.
• W1760504346 hasConcept C2779321808 @default.
• W1760504346 hasConcept C2779429289 @default.
• W1760504346 hasConcept C2780350996 @default.
• W1760504346 hasConcept C29730261 @default.
• W1760504346 hasConcept C71924100 @default.
• W1760504346 hasConcept C98274493 @default.
• W1760504346 hasConceptScore W1760504346C126322002 @default.
• W1760504346 hasConceptScore W1760504346C141071460 @default.
• W1760504346 hasConceptScore W1760504346C143998085 @default.
• W1760504346 hasConceptScore W1760504346C2776553716 @default.
• W1760504346 hasConceptScore W1760504346C2776694085 @default.
• W1760504346 hasConceptScore W1760504346C2776755627 @default.
• W1760504346 hasConceptScore W1760504346C2777096885 @default.
• W1760504346 hasConceptScore W1760504346C2777132456 @default.
• W1760504346 hasConceptScore W1760504346C2778239845 @default.
• W1760504346 hasConceptScore W1760504346C2779321808 @default.
• W1760504346 hasConceptScore W1760504346C2779429289 @default.
• W1760504346 hasConceptScore W1760504346C2780350996 @default.
• W1760504346 hasConceptScore W1760504346C29730261 @default.
• W1760504346 hasConceptScore W1760504346C71924100 @default.
• W1760504346 hasConceptScore W1760504346C98274493 @default.
• W1760504346 hasIssue "3" @default.
• W1760504346 hasLocation W17605043461 @default.
• W1760504346 hasOpenAccess W1760504346 @default.
• W1760504346 hasPrimaryLocation W17605043461 @default.
• W1760504346 hasRelatedWork W2036553841 @default.
• W1760504346 hasRelatedWork W2094790699 @default.
• W1760504346 hasRelatedWork W2243812748 @default.
• W1760504346 hasRelatedWork W2544232533 @default.
• W1760504346 hasRelatedWork W2800973874 @default.
• W1760504346 hasRelatedWork W3034993153 @default.
• W1760504346 hasRelatedWork W3193891658 @default.
• W1760504346 hasRelatedWork W4299333187 @default.
• W1760504346 hasRelatedWork W4313289911 @default.
• W1760504346 hasRelatedWork W4939904 @default.
• W1760504346 hasVolume "2" @default.
• W1760504346 isParatext "false" @default.
• W1760504346 isRetracted "false" @default.
• W1760504346 magId "1760504346" @default.
• W1760504346 workType "article" @default.